Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis

References

• Tsoutsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys 2006; 66:1281-93; PMID:17126203; http://dx.doi.org/10.1016/j.ijrobp.2006.08.058
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005; 201:925-35; PMID:15781583; http://dx.doi.org/10.1084/jem.20041393
   PubMed Web of Science ®Google Scholar
• Benveniste MF, Welsh J, Godoy MC, Betancourt SL, Mawlawi OR, Munden RF. New era of radiotherapy: an update in radiation-induced lung disease. Clin Radiol 2013; 68:e275-90; PMID:23473474; http://dx.doi.org/10.1016/j.crad.2013.01.013
   PubMed Web of Science ®Google Scholar
• Nicolay NH, Lopez Perez R, Debus J, Huber PE. Mesenchymal stem cells - A new hope for radiotherapy-induced tissue damage? Cancer Lett 2015; 366:133-40; PMID:26166559; http://dx.doi.org/10.1016/j.canlet.2015.06.012
   PubMed Web of Science ®Google Scholar
• Kong FM, Zhao L, Hayman JA. The role of radiation therapy in thoracic tumors. Hematol Oncol Clin North Am 2006; 20:363-400; PMID:16730299; http://dx.doi.org/10.1016/j.hoc.2006.01.021
   PubMed Web of Science ®Google Scholar
• Roeder F, Friedrich J, Timke C, Kappes J, Huber P, Krempien R, Debus J, Bischof M. Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer. Strahlenther Onkol 2010; 186:149-56; PMID:20165822; http://dx.doi.org/10.1007/s00066-010-2018-4
   PubMed Web of Science ®Google Scholar
• Yarnold J, Brotons MC. Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol 2010; 97:149-61; PMID:20888056; http://dx.doi.org/10.1016/j.radonc.2010.09.002
   PubMed Web of Science ®Google Scholar
• Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 1995; 33:99-109; PMID:7642437; http://dx.doi.org/10.1016/0360-3016(95)00095-G
   PubMed Web of Science ®Google Scholar
• Williams JP, Johnston CJ, Finkelstein JN. Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction? Curr Drug Targets 2010; 11:1386-94; PMID:20583979; http://dx.doi.org/10.2174/1389450111009011386
   PubMed Web of Science ®Google Scholar
• Andrianifahanana M, Wilkes MC, Gupta SK, Rahimi RA, Repellin CE, Edens M, Wittenberger J, Yin X, Maidl E, Becker J et al. ProfibroticTGFbeta responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases. FASEB J 2013; 27(11):4444-54; PMID:23913859; http://dx.doi.org/10.1096/fj.12-224907
   PubMed Web of Science ®Google Scholar
• Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001; 107:1529-36; PMID:11413160; http://dx.doi.org/10.1172/JCI12568
   PubMed Web of Science ®Google Scholar
• Farooqi AA, Waseem S, Riaz AM, Dilawar BA, Mukhtar S, Minhaj S, Waseem MS, Daniel S, Malik BA, Nawaz A et al. PDGF: the nuts and bolts of signalling toolbox. Tumour Biol 2011; 32:1057-70; PMID:21769672; http://dx.doi.org/10.1007/s13277-011-0212-3
   PubMed Web of Science ®Google Scholar
• Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29:976-85; PMID:17301095; http://dx.doi.org/10.1183/09031936.00152106
   PubMed Web of Science ®Google Scholar
• Flechsig P, Dadrich M, Bickelhaupt S, Jenne J, Hauser K, Timke C, Peschke P, Hahn EW, Grone HJ, Yingling J et al. LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res 2012; 18:3616-27; PMID:22547771; http://dx.doi.org/10.1158/1078-0432.CCR-11-2855
   PubMed Web of Science ®Google Scholar
• Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, Yang Z, Devitt ML, Horan GS, Weinreb PH, Lukashev ME et al. Inhibition of integrin α(v)beta6, an activator of latent transforming growth factor-β, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 2008; 177:82-90; PMID:17916808; http://dx.doi.org/10.1164/rccm.200706-806OC
   PubMed Web of Science ®Google Scholar
• Cigna N, Farrokhi Moshai E, Brayer S, Marchal-Somme J, Wemeau-Stervinou L, Fabre A, Mal H, Leseche G, Dehoux M, Soler P et al. The hedgehog system machinery controls transforming growth factor-β-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis. Am J Pathol 2012; 181:2126-37; PMID:23031257; http://dx.doi.org/10.1016/j.ajpath.2012.08.019
   PubMed Web of Science ®Google Scholar
• Leask A, Abraham DJ. TGF-β signaling and the fibrotic response. FASEB J 2004; 18:816-27; PMID:15117886; http://dx.doi.org/10.1096/fj.03-1273rev
   PubMed Web of Science ®Google Scholar
• Attisano L, Wrana JL. Signal transduction by the TGF-β superfamily. Science 2002; 296:1646-7; PMID:12040180; http://dx.doi.org/10.1126/science.1071809
   PubMed Web of Science ®Google Scholar
• Rodon J, Carducci MA, Sepúlveda JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly A et al. Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-β (TGF-ß) receptor I kinase inhibitor, LY2157299 monohydrate (LY). Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago 2013; Abstract Number 2016.
   Google Scholar
• Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Troconiz IF. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. Eur J Cancer 2008; 44:142-50; PMID:18039567; http://dx.doi.org/10.1016/j.ejca.2007.10.008
   PubMed Web of Science ®Google Scholar
• Tsukui T, Ueha S, Abe J, Hashimoto S, Shichino S, Shimaoka T, Shand FH, Arakawa Y, Oshima K, Hattori M et al. Qualitative rather than quantitative changes are hallmarks of fibroblasts in bleomycin-induced pulmonary fibrosis. Am J Pathol 2013; 183:758-73; PMID:23886891; http://dx.doi.org/10.1016/j.ajpath.2013.06.005
   PubMed Web of Science ®Google Scholar
• Schneider DJ, Lindsay JC, Zhou Y, Molina JG, Blackburn MR. Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease. FASEB J 2010; 24:70-80; PMID:19720619; http://dx.doi.org/10.1096/fj.09-140772
   PubMed Web of Science ®Google Scholar
• Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 2012; 159:218-27; PMID:22424426; http://dx.doi.org/10.1016/j.trsl.2012.01.012
   PubMed Web of Science ®Google Scholar
• Koli K, Myllarniemi M, Keski-Oja J, Kinnula VL. Transforming growth factor-β activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid Redox Signal 2008; 10:333-42; PMID:17961070; http://dx.doi.org/10.1089/ars.2007.1914
   PubMed Web of Science ®Google Scholar
• Ingram JL, Bonner JC. EGF and PDGF receptor tyrosine kinases as therapeutic targets for chronic lung diseases. Curr Mol Med 2006; 6:409-21; PMID:16900664; http://dx.doi.org/10.2174/156652406777435426
   PubMed Web of Science ®Google Scholar
• Rube CE, Uthe D, Schmid KW, Richter KD, Wessel J, Schuck A, Willich N, Rube C. Dose-dependent induction of transforming growth factor β (TGF-β) in the lung tissue of fibrosis-prone mice after thoracic irradiation. Int J Radiat Oncol Biol Phys 2000; 47:1033-42; PMID:10863076; http://dx.doi.org/10.1016/S0360-3016(00)00482-X
   PubMed Web of Science ®Google Scholar
• Yi ES, Bedoya A, Lee H, Chin E, Saunders W, Kim SJ, Danielpour D, Remick DG, Yin S, Ulich TR. Radiation-induced lung injury in vivo: expression of transforming growth factor-β precedes fibrosis. Inflammation 1996; 20:339-52; PMID:8872498; http://dx.doi.org/10.1007/BF01486737
   PubMed Web of Science ®Google Scholar
• Thornton SC, Walsh BJ, Bennett S, Robbins JM, Foulcher E, Morgan GW, Penny R, Breit SN. Both in vitro and in vivo irradiation are associated with induction of macrophage-derived fibroblast growth factors. Clin Exp Immunol 1996; 103:67-73; PMID:8565289; http://dx.doi.org/10.1046/j.1365-2249.1996.898598.x
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Miyoshi K, Oda N, Watanabe M, Miyake H, Chan J, Wang X, Sun L, Tang C, McMahon G et al. Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis. Circ Res 2001; 88:630-6; PMID:11282898; http://dx.doi.org/10.1161/01.RES.88.6.630
   PubMed Web of Science ®Google Scholar
• Li M, Ping G, Plathow C, Trinh T, Lipson KE, Hauser K, Krempien R, Debus J, Abdollahi A, Huber PE. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells. BMC Cancer 2006; 6:79; PMID:16556328; http://dx.doi.org/10.1186/1471-2407-6-79
   PubMed Web of Science ®Google Scholar
• Waller CF. Imatinibmesylate. Recent Results Cancer Res 2010; 184:3-20; PMID:20072827; http://dx.doi.org/10.1007/978-3-642-54490-3_1
   PubMedGoogle Scholar
• Rhee CK, Lee SH, Yoon HK, Kim SC, Lee SY, Kwon SS, Kim YK, Kim KH, Kim TJ, Kim JW. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respiration 2011; 82:273-87; PMID:21659722; http://dx.doi.org/10.1159/000327719
   PubMed Web of Science ®Google Scholar
• Bonner JC, Badgett A, Lindroos PM, Osornio-Vargas AR. Transforming growth factor β 1 downregulates the platelet-derived growth factor α-receptor subtype on human lung fibroblasts in vitro. Am J Respir Cell Mol Biol 1995; 13:496-505; PMID:7546780; http://dx.doi.org/10.1165/ajrcmb.13.4.7546780
   PubMed Web of Science ®Google Scholar
• Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 2012; 3:371-94; PMID:22564882; http://dx.doi.org/10.18632/oncotarget.477
   PubMed Web of Science ®Google Scholar
• Konecny GE. Emerging strategies for the dual inhibition of HER2-positive breast cancer. Current Opin Obstet Gynecol 2013; 25:55-65; PMID:23241641; http://dx.doi.org/10.1097/GCO.0b013e32835c5e90
   PubMed Web of Science ®Google Scholar
• Socinski MA. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer. Cancer Treat Rev 2011; 37:611-7; PMID:21641723; http://dx.doi.org/10.1016/j.ctrv.2011.04.003
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824; PMID:21471066; http://dx.doi.org/10.1164/rccm.2009-040GL
   PubMed Web of Science ®Google Scholar
• King TE, Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-92; PMID:24836312; http://dx.doi.org/10.1056/NEJMoa1402582
   PubMed Web of Science ®Google Scholar
• Yang Y, Ye Y, Lin X, Wu K, Yu M. Inhibition of pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transition of human lens epithelial cells line SRA01/04. PloSOne 2013; 8:e56837; PMID:23437252; http://dx.doi.org/10.1371/journal.pone.0056837
   PubMed Web of Science ®Google Scholar
• Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F et al. Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med 2014; 108:1023-30; PMID:24834811; http://dx.doi.org/10.1016/j.rmed.2014.04.011
   PubMed Web of Science ®Google Scholar
• Sharplin J, Franko AJ. A quantitative histological study of strain-dependent differences in the effects of irradiation on mouse lung during the intermediate and late phases. Radiat Res 1989; 119:15-31; PMID:2756106; http://dx.doi.org/10.2307/3577364
   PubMed Web of Science ®Google Scholar
• Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translationallevel. Am J Physiol 1999; 276:L311-8; PMID:9950894.
   Google Scholar
• Maeda A, Hiyama K, Yamakido H, Ishioka S, Yamakido M. Increased expression of platelet-derived growth factor A and insulin-like growth factor-I in BAL cells during the development of bleomycin-induced pulmonary fibrosis in mice. Chest 1996; 109:780-6; PMID:8617091; http://dx.doi.org/10.1378/chest.109.3.780
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinibmesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114:1308-16; PMID:15520863; http://dx.doi.org/10.1172/JCI200419603
   PubMed Web of Science ®Google Scholar
• Kirk JM, Da Costa PE, Turner-Warwick M, Littleton RJ, Laurent GJ. Biochemical evidence for an increased and progressive deposition of collagen in lungs of patients with pulmonary fibrosis. Clin Sci 1986; 70:39-45; PMID:3943276; http://dx.doi.org/10.1042/cs0700039
   PubMed Web of Science ®Google Scholar
• Yamashita M, Yamauchi K, Chiba R, Iwama N, Date F, Shibata N, Kumagai H, Risteli J, Sato S, Takahashi T et al. The definition of fibrogenic processes in fibroblastic foci of idiopathic pulmonary fibrosis based on morphometric quantification of extracellular matrices. Hum Pathol 2009; 40:1278-87; PMID:19386353; http://dx.doi.org/10.1016/j.humpath.2009.01.014
   PubMed Web of Science ®Google Scholar
• Sabo-Attwood T, Ramos-Nino ME, Eugenia-Ariza M, Macpherson MB, Butnor KJ, Vacek PC, McGee SP, Clark JC, Steele C, Mossman BT. Osteopontin modulates inflammation, mucin production, and gene expression signatures after inhalation of asbestos in a murine model of fibrosis. Am J Pathol 2011; 178:1975-85; PMID:21514415; http://dx.doi.org/10.1016/j.ajpath.2011.01.048
   PubMed Web of Science ®Google Scholar
• Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005; 2:e251; PMID:16128620; http://dx.doi.org/10.1371/journal.pmed.0020251
   PubMed Web of Science ®Google Scholar
• Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-β targeted cancer therapy. Int J Biol Sci 2012; 8:964-78; PMID:22811618; http://dx.doi.org/10.7150/ijbs.4564
   PubMed Web of Science ®Google Scholar
• Kong X, Horiguchi N, Mori M, Gao B. Cytokines and STATs in Liver Fibrosis. Front Physiol 2012; 3:69; PMID:22493582; http://dx.doi.org/10.3389/fphys.2012.00069
   PubMed Web of Science ®Google Scholar
• Nazha A, Khoury JD, Rampal RK, Daver N. Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications. Oncologist 2015; 20:1154-60; PMID:26304912; http://dx.doi.org/10.1634/theoncologist.2015-0094
   PubMed Web of Science ®Google Scholar
• Ryter SW, Choi AM, Kim HP. Profibrogenic phenotype in caveolin-1 deficiency via differential regulation of STAT-1/3 proteins. Biochem Cell Biol 2014; 92:370-8; PMID:25263949; http://dx.doi.org/10.1139/bcb-2014-0075
   PubMed Web of Science ®Google Scholar
• Pedroza M, Le TT, Lewis K, Karmouty-Quintana H, To S, George AT, Blackburn MR, Tweardy DJ, Agarwal SK. STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J 2015; 30(1):129-40; PMID:26324850
   PubMed Web of Science ®Google Scholar
• Tang J, Liu CY, Lu MM, Zhang J, Mei WJ, Yang WJ, Xie YY, Huang L, Peng ZZ, Yuan QJ et al. Fluorofenidone protects against renal fibrosis by inhibiting STAT3 tyrosine phosphorylation. Mol Cell Biochem 2015; 407:77-87; PMID:26033204; http://dx.doi.org/10.1007/s11010-015-2456-5
   PubMed Web of Science ®Google Scholar
• Wiezel D, Assadi MH, Landau D, Troib A, Kachko L, Rabkin R, Segev Y. Impaired renal growth hormone JAK/STAT5 signaling in chronic kidney disease. Nephrol Dial Transpl 2014; 29:791-9; PMID:24463190; http://dx.doi.org/10.1093/ndt/gfu003
   PubMed Web of Science ®Google Scholar
• TimkeC, ZieherH, RothA, HauserK, LipsonKE, WeberKJ, DebusJ, AbdollahiA, HuberPE. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008; 14:2210-9; PMID:18381963; http://dx.doi.org/10.1158/1078-0432.CCR-07-1893
   PubMed Web of Science ®Google Scholar